Home

Christopher Ray Aker

CIK 1762611 · Sr. VP & General Counsel · last filed 2025-06-27

Christopher Ray Aker is a Sr. VP & General Counsel who has filed 29 SEC Form 4 insider transactions across 1 company since 2019. The most recent filing, for RGLS, was dated Jun 27, 2025. Across all open-market trades the lifetime net is −$86.3K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

29

Lifetime Open-Market Net

-$86.3K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Regulus Therapeutics Inc. (RGLS) Delisted Sr. VP & General Counsel 83,125 $8.16 $678.3K -$86.3K 29 2025-06-27

Recent Filings

29 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2025-06-27 Regulus Therapeutics Inc. (RGLS) Delisted Mixed −143,921 $0 EDGAR
2025-01-31 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) — $0 EDGAR
2025-01-15 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −43,635 -$55.1K EDGAR
2025-01-10 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) +84,125 $113.4K EDGAR
2024-05-21 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) — $0 EDGAR
2024-01-18 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −5,468 -$6.5K EDGAR
2024-01-17 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) +11,250 $0 EDGAR
2023-08-14 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) — $0 EDGAR
2023-01-17 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) — $0 EDGAR
2023-01-17 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 29
Page 1 of 3
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.